In a report published Wednesday, Morgan Stanley analyst Vincent Andrews reiterated an Equal-Weight rating on Praxair PX, but removed the $140.00 price target.
In the report, Morgan Stanley noted, “We expect a neutral to positive response to Prax's 1Q14 results. Neutral as: i) Praxair's results beat our recently reduced EPS estimate (note: interest expense was a $0.02 headwind relative to our forecast), but was in line with consensus, and in the middle of the company's guidance range; ii) The company narrowed its guidance range for the full year by $0.05 on both sides to $6.30-$6.55 versus consensus of $6.47 and MSe of $6.45 (2Q guidance of $1.55-$1.60 compares to consensus of $1.62 and MSe of $1.57); and iii) ROIC declined both year-over-year and sequentially, but management expects it to increase in the back half of the year.
"Positive because: i) Volume grew year-over-year in all regions; ii) Price was positive in all regions except for Europe where it was flat. F/X was a 4% drag on operating profit (negative in South American, partially offset by Europe) and will be a 10% drag in South America for the full year.”
Praxair closed on Tuesday at $131.97.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in